Dear Pat, As of the 6th HLDA Workshop held in Osaka, Japan last November, CDw109 antibodies have shed their 'working' designation and are now CD109 antibodies. CDw109 antibody clone D2 was made by Dr. Robert W. Finberg, Dana-Farber Cancer Institute, 44 Binney Street, JFB 424, Boston MA 02115 (Haregewoin A., Solomon K., Hom R.C., Soman G., Bergelson J.M., Bhan A.K. and Finberg R.W. Cellular Immunology 156, 357-70, 1994). This antibody was raised against a Gibbon CTLL cell line and was found to cross-react with the human CDw109 antigen as defined by antibodies 8A3 and 7D1 (Sutherland D.R., Yeo E., Ryan A., Mills G.B., Bailey D. and Baker M.A. Blood 77 84-93, 1991) at the 5th Workshop held in Boston in 1993 (Sutherland DR and Yeo EL. Cluster report: CDw109. In: Leukocyte Typing V (Schlossman S., et al eds.) Oxford University Press, Oxford pp 1767-1769, 1995). A number of other CD109 antibodies were defined at the 6th Workshop and if you would like any further information on these reagents, you can contact me on one of the numbers listed below. I hope this is helpful, D. Robert Sutherland, Chair, CD109 section, Endothelial Cell Section, 6th HLDA Workshop, Oncology Research, The Toronto Hospital. Tel: 416 340 4054 Fax: 415-340 3453
This archive was generated by hypermail 2b29 : Wed Apr 03 2002 - 11:49:39 EST